JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

被引：0

作者：

Toshihiko Wakabayashi

Atsushi Natsume

Junki Mizusawa

Hiroshi Katayama

Haruhiko Fukuda

Minako Sumi

Ryo Nishikawa

Yoshitaka Narita

Yoshihiro Muragaki

Takashi Maruyama

Tamio Ito

Takaaki Beppu

Hideo Nakamura

Takamasa Kayama

Shinya Sato

Motoo Nagane

Kazuhiko Mishima

Yoko Nakasu

Kaoru Kurisu

Fumiyuki Yamasaki

Kazuhiko Sugiyama

Takanori Onishi

Yasuo Iwadate

Mizuhiko Terasaki

Hiroyuki Kobayashi

Akira Matsumura

Eiichi Ishikawa

Hikaru Sasaki

Akitake Mukasa

Takayuki Matsuo

Hirofumi Hirano

Toshihiro Kumabe

Nobusada Shinoura

Naoya Hashimoto

Tomokazu Aoki

Akio Asai

Tatsuya Abe

Atsuo Yoshino

Yoshiki Arakawa

Kenichiro Asano

Koji Yoshimoto

Soichiro Shibui

机构：

[1] Nagoya University Graduate School of Medicine,Department of Neurosurgery

[2] National Cancer Center Hospital,JCOG (Japan Clinical Oncology Group) Data Center/Operations Office

[3] Cancer Institute Hospital,Radiation Oncology Department

[4] Saitama Medical University International Medical Center,Department of Neuro

[5] National Cancer Center Hospital,Oncology/Neurosurgery

[6] Tokyo Women’s Medical University,Department of Neurosurgery and Neuro

[7] Nakamura Memorial Hospital,Oncology

[8] Iwate Medical University,Department of Neurosurgery

[9] Kumamoto University Graduate School of Medicine,Department of Neurosurgery

[10] Yamagata University Graduate School of Medicine,Department of Neurosurgery

[11] Kyorin University Faculty of Medicine,Department of Neurosurgery

[12] Shizuoka Cancer Center,Department of Neurosurgery

[13] Hiroshima University,Department of Neurosurgery

[14] Graduate School of Biomedical and Health Sciences,Department of Neurosurgery

[15] Hiroshima University Hospital,Department of Neurosurgery

[16] Ehime University Graduate School of Medicine,Department of Clinical Oncology & Neuro

[17] Chiba University Graduate School of Medicine,oncology Program

[18] Kurume University Graduate School of Medicine,Department of Neurosurgery

[19] Hokkaido University Graduate School of Medicine,Department of Neurosurgery

[20] University of Tsukuba,Department of Neurosurgery

[21] Keio University School of Medicine,Department of Neurosurgery

[22] The University of Tokyo Hospital,Department of Neurosurgery, Faculty of Medicine

[23] Nagasaki University Graduate School of Medicine,Department of Neurosurgery

[24] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Neurosurgery

[25] Tohoku University Graduate School of Medicine,Department of Neurosurgery

[26] Kitasato University School of Medicine,Department of Neurosurgery

[27] Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital,Department of Neurosurgery

[28] Osaka University Graduate School of Medicine,Department of Neurosurgery

[29] Kitano Hospital,Department of Neurosurgery

[30] Kansai Medical University,Department of Neurosurgery

[31] Oita University Faculty of Medicine,Department of Neurosurgery

[32] Nihon University Graduate School of Medicine,Department of Neurosurgery

[33] Kyoto University Graduate School of Medicine,Department of Neurosurgery

[34] Hirosaki University Graduate School of Medicine,Department of Neurological Surgery

[35] Kyushu University,Department of Neurosurgery

来源：

Journal of Neuro-Oncology | 2018年 / 138卷

关键词：

Glioblastoma; Interferon-beta; Temozolomide; MGMT; RCT;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 636

页数：9

共 50 条

[21] AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
O. L. Chinot
T. de La Motte Rouge
N. Moore
A. Zeaiter
A. Das
H. Phillips
Z. Modrusan
T. Cloughesy
Advances in Therapy, 2011, 28 : 334 - 340
[22] A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501)
Rosenfeld, M. R.
Chamberlain, M. C.
Grossman, S. A.
Peereboom, D. M.
Lesser, G. J.
Batchelor, T. T.
Desideri, S.
Salazar, A. M.
Ye, X.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[23] Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Carmen Balana
Ramon De Las Penas
Juan Manuel Sepúlveda
Miguel J. Gil-Gil
Raquel Luque
Oscar Gallego
Cristina Carrato
Carolina Sanz
Gaspar Reynes
Ana Herrero
Jose Luis Ramirez
Pedro Pérez-Segura
Alfonso Berrocal
Jose Maria Vieitez
Almudena Garcia
Sergio Vazquez-Estevez
Sergi Peralta
Isaura Fernandez
Ivan Henriquez
Maria Martinez-Garcia
Juan Jose De la Cruz
Jaume Capellades
Pilar Giner
Salvador Villà
Journal of Neuro-Oncology, 2016, 127 : 569 - 579
[24] Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Balana, Carmen
De Las Penas, Ramon
Manuel Sepulveda, Juan
Gil-Gil, Miguel J.
Luque, Raquel
Gallego, Oscar
Carrato, Cristina
Sanz, Carolina
Reynes, Gaspar
Herrero, Ana
Luis Ramirez, Jose
Perez-Segura, Pedro
Berrocal, Alfonso
Maria Vieitez, Jose
Garcia, Almudena
Vazquez-Estevez, Sergio
Peralta, Sergi
Fernandez, Isaura
Henriquez, Ivan
Martinez-Garcia, Maria
Jose De la Cruz, Juan
Capellades, Jaume
Giner, Pilar
Villa, Salvador
JOURNAL OF NEURO-ONCOLOGY, 2016, 127 (03) : 569 - 579
[25] Anlotinib plus radiotherapy-temozolomide for newly diagnosed glioblastoma: A prospective, multicenter phase II study.
Lai, Shuzhen
Chen, Yuan Yuan Yuan
Li, Peijing
Jiang, Fagui
Liu, Xiaohui
Tao, Changjuan
Huang, Jing
Tang, Yiqiang
Liu, Zhigang
Shen, Guoping
Li, Chaoming
Xie, Tieming
Lu, Fangxiao
Liu, Guihong
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, Mark R.
Wang, Meihua
Aldape, Kenneth D.
Stupp, Roger
Hegi, Monika E.
Jaeckle, Kurt A.
Armstrong, Terri S.
Wefel, Jeffrey S.
Won, Minhee
Blumenthal, Deborah T.
Mahajan, Anita
Schultz, Christopher J.
Erridge, Sara
Baumert, Brigitta
Hopkins, Kristen I.
Tzuk-Shina, Tzahala
Brown, Paul D.
Chakravarti, Arnab
Curran, Walter J., Jr.
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4085 - +
[27] Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Anocef phase II trial
Reyes-Botero, German
Honnorat, Jerome
Chinot, Oliver L.
Taillandier, Luc
Catry-Thomas, Isabelle
Barriere, Jerome
Guillamo, Jean Sebastien
Fabbro, Michel
Frappaz, Didier
Amiel, Alexandra Benouaich
Le Rhun, Emilie
Campello, Chantal
Tennevet, Isabelle
Ghiringhelli, Francois
Tanguy, Marie-Laure
Mokhtari, Karima
Delattre, Jean-Yves
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Herrlinger, Ulrich
Rieger, Johannes
Koch, Dorothee
Loeser, Simon
Blaschke, Britta
Kortmann, Rolf-Dieter
Steinbach, Joachim P.
Hundsberger, Thomas
Wick, Wolfgang
Meyermann, Richard
Tan, Ta-Chih
Sommer, Clemens
Bamberg, Michael
Reifenberger, Guido
Weller, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4412 - 4417
[29] Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
Molaie, Donna
Lai, Albert
Ellingson, Benjamin M.
Thien Nguyen
Bahng, Hye Hyun
Filka, Emese
Green, Stacey
Pope, Whitney B.
Leng, Mei
Yong, William H.
Green, Richard M.
Polikoff, Jonathan
Spier, Liz
Iwamoto, Fabio Massaiti
Lassman, Andrew B.
Cloughesy, Timothy Francis
Nghiemphu, Phioanh Leia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
Chang, SM
Lamborn, KR
Malec, M
Larson, D
Wara, W
Sneed, P
Rabbitt, J
Page, M
Nicholas, MK
Prados, MD
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02): : 353 - 357

← 1 2 3 4 5 →